BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 17313541)

  • 1. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
    Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
    Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.
    Arslan S; Erol MK; Bozkurt E; Acikel M; Gundogdu F; Atesal S; Senocak H
    Int J Cardiovasc Imaging; 2007 Oct; 23(5):549-55. PubMed ID: 17171429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
    Li N; Li Y; Wang F; Jiang W; Huang J; Xu Z; Hua L; Hua C; Huang Y; Wu Y; Li F
    Clin Cardiol; 2007 Sep; 30(9):469-74. PubMed ID: 17803204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
    Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
    Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
    Wang F; Xu ZM; Wang L; Bian WY; Jia X; Duan B; Li W; Li YS
    Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):490-4. PubMed ID: 16080835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
    Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-brain natriuretic peptide plasma levels, left ventricular dimensions and ejection fraction in acute dyspnoea.
    Shaikh K; Hanif B; Siddique AA; Shaikh MY; Khan MN
    J Coll Physicians Surg Pak; 2012 Dec; 22(12):751-5. PubMed ID: 23217478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
    Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
    Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
    Kaya MG; Sarli B; Akpek M; Kaya EG; Yarlioglues M; Topsakal R; Lam YY
    Cardiol J; 2014; 21(4):434-41. PubMed ID: 24142686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NT-proBNP in monitoring treatment of patients with congestive heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Clin Lab; 2007; 53(1-2):35-9. PubMed ID: 17323823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acute effect of Metoprolol upon NT-proBNP level in patients with congestive heart failure.
    Zdrenghea D; Pop D; Ilea M; Bodisz G; Mălai A; Zdrenghea M
    Rom J Intern Med; 2009; 47(1):35-40. PubMed ID: 19886067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
    Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
    Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects].
    Wu YR; Chen SB; Huang MR; Zhang YQ; Sun K; Chen S
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):161-4. PubMed ID: 15833183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.
    Kohno T; Yoshikawa T; Yoshizawa A; Nakamura I; Anzai T; Satoh T; Ogawa S
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):347-55. PubMed ID: 16382297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.